Surgical, Radiation, and Systemic Treatments of Patients with Thymic Epithelial Tumours
- MeSH Terms
- thymoma, thymus cancer, thymus neoplasms, antineoplastic agent, drug therapy, chemotherapy, adjuvant chemotherapy, cancer adjuvant chemotherapy, cancer chemotherapy, cancer combination chemotherapy, combination chemotherapy, multimodality cancer therapy, antineoplastic combined chemotherapy protocols, surgery, thoracic surgery, thymectomy, sternotomy, radiotherapy, cancer radiotherapy, preoperative radiotherapy, systemic therapy, imatinib mesylate, imatinib, cixutumumab, sunitinib, saracatinib, everolimus, octreotide, pembrolizumab, nivolumab, atezolizumab, cisplatin, carboplatin, platinum, Gleevec, Glivec, Sutent, Zortress, Certican, Afinitor, Votubia, Evertor, Sandostatin, Bynfezia Pen, Keytruda, lambrolizumab, Opdivo, MDX1106, Tecentriq, MPDL3280A, CDDP, CBDCA, STI-571, ONO-4538, MK-3475, BMS-936558, thymic, thymus
- Guideline Contact
- Emily Vella; [email protected]
- Keywords
- thymoma, thymus cancer, adjuvant chemotherapy, combination chemotherapy, cancer radiotherapy, systemic therapy
- Date for Review
- In Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario), we have an annual review process for each guideline after it is completed. Guidelines are reviewed every fall after they are older than 1 year.
- Publication Date
- 2022-03-10
- Date of Last Evidence Search
- 2021-08-26
- Methods Applied
- Systematic review-based, Evidence quality assessment, Externally reviewed, GRADE approach
- Publication Scope
- Guidelines
- treatment
- Countries of Application
- Canada
- Guideline Publication Status
- Published
- Languages
- English
- Authors
- PEBC (Program in evidenced-based care)
- Publication Year
- 2022